IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
Clinical trial NCT04945421 · COMPLETED
Trial details
- NCT number
- NCT04945421
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-23
- Primary completion
- 2022-04-25
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.